India’s Drug-Price Agency Rankles Drug Makers
This article was originally published in PharmAsia News
Executive Summary
India's drug-pricing regulator is flexing its muscles in going after drug makers for allegedly charging more for their products than rules allow. The National Pharmaceutical Pricing Authority has been going after drug makers even as the two entities are involved in court litigation over the price limits. The fight between the two entities over price caps has led to a stack of court cases, partly because of a concern of a conflict between regulations and policy. But the chief problem may be a lack of coordination between the NPPA and the country's regulator of quality, the Drug Controller General of India. (Click here for more
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.